WO2023174948A3 - Compositions having improved bioavailability of therapeutics and uses thereof - Google Patents

Compositions having improved bioavailability of therapeutics and uses thereof Download PDF

Info

Publication number
WO2023174948A3
WO2023174948A3 PCT/EP2023/056506 EP2023056506W WO2023174948A3 WO 2023174948 A3 WO2023174948 A3 WO 2023174948A3 EP 2023056506 W EP2023056506 W EP 2023056506W WO 2023174948 A3 WO2023174948 A3 WO 2023174948A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
present specification
compositions
therapeutics
fibrates
Prior art date
Application number
PCT/EP2023/056506
Other languages
French (fr)
Other versions
WO2023174948A2 (en
Inventor
Daniel Gooding
John Brew
Robin M. Bannister
Original Assignee
TRx Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/en
Application filed by TRx Biosciences Limited filed Critical TRx Biosciences Limited
Priority to AU2023233811A priority Critical patent/AU2023233811A1/en
Publication of WO2023174948A2 publication Critical patent/WO2023174948A2/en
Publication of WO2023174948A3 publication Critical patent/WO2023174948A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present specification discloses pharmaceutical composition disclosed herein comprises one or more fibrates, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more fibrates into the disclosed pharmaceutical compositions. The present specification further discloses methods and uses of the disclosed pharmaceutical compositions in the treatment of an inflammation and/or neuroinflammation.
PCT/EP2023/056506 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof WO2023174948A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023233811A AU2023233811A1 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263269330P 2022-03-14 2022-03-14
US63/269,330 2022-03-14
EPPCT/EP2022/058180 2022-03-28
PCT/EP2022/058180 WO2022207580A2 (en) 2021-03-27 2022-03-28 Compositions having improved bioavailability of therapeutics

Publications (2)

Publication Number Publication Date
WO2023174948A2 WO2023174948A2 (en) 2023-09-21
WO2023174948A3 true WO2023174948A3 (en) 2023-10-26

Family

ID=85571360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/056506 WO2023174948A2 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Country Status (2)

Country Link
AU (1) AU2023233811A1 (en)
WO (1) WO2023174948A2 (en)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
CN101507707A (en) * 2009-04-08 2009-08-19 邓菊娟 Fasudil hydrochloride lipo-microballoons carrier preparation and preparation method thereof
WO2010041051A1 (en) * 2008-10-07 2010-04-15 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010075065A2 (en) * 2008-12-15 2010-07-01 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
CN102813639A (en) * 2011-06-08 2012-12-12 中国疾病预防控制中心寄生虫病预防控制所 Mebendazole soft capsule
EP2220073B1 (en) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
JP2015508099A (en) * 2012-02-21 2015-03-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Cyclic diaminopyridine derivative
US20150150881A1 (en) * 2013-12-04 2015-06-04 Gilead Sciences, Inc. Methods for treating cancers
US9339553B2 (en) * 2010-09-01 2016-05-17 Peking University Liquid compositions of insoluble drugs and preparation methods thereof
US20180251422A1 (en) * 2017-03-03 2018-09-06 Rgenix, Inc. Formulations with improved stability
WO2020217235A1 (en) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
CN113546045A (en) * 2021-08-18 2021-10-26 浙江大学 Nanometer preparation for recovering tumor microenvironment inactivated dendritic cell function and application thereof
US20210346302A1 (en) * 2018-10-15 2021-11-11 Cipla Limited Pharmaceutical Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
EP2220073B1 (en) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
WO2010041051A1 (en) * 2008-10-07 2010-04-15 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010075065A2 (en) * 2008-12-15 2010-07-01 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
CN101507707A (en) * 2009-04-08 2009-08-19 邓菊娟 Fasudil hydrochloride lipo-microballoons carrier preparation and preparation method thereof
US9339553B2 (en) * 2010-09-01 2016-05-17 Peking University Liquid compositions of insoluble drugs and preparation methods thereof
CN102813639A (en) * 2011-06-08 2012-12-12 中国疾病预防控制中心寄生虫病预防控制所 Mebendazole soft capsule
JP2015508099A (en) * 2012-02-21 2015-03-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Cyclic diaminopyridine derivative
US20150150881A1 (en) * 2013-12-04 2015-06-04 Gilead Sciences, Inc. Methods for treating cancers
US20180251422A1 (en) * 2017-03-03 2018-09-06 Rgenix, Inc. Formulations with improved stability
US20210346302A1 (en) * 2018-10-15 2021-11-11 Cipla Limited Pharmaceutical Formulation
WO2020217235A1 (en) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
CN113546045A (en) * 2021-08-18 2021-10-26 浙江大学 Nanometer preparation for recovering tumor microenvironment inactivated dendritic cell function and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
METIBEMU D. SAMUEL ET AL: "Exploring receptor tyrosine kinases-inhibitors in Cancer treatments", EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, vol. 20, no. 1, 1 December 2019 (2019-12-01), XP093047319, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s43042-019-0035-0/fulltext.html> [retrieved on 20230516], DOI: 10.1186/s43042-019-0035-0 *

Also Published As

Publication number Publication date
AU2023233811A1 (en) 2024-09-19
WO2023174948A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
WO2022207580A3 (en) Compositions having improved bioavailability of therapeutics
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
CA2701482C (en) Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
NZ734905A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2009141617A (en) APPLICATION OF SELECTED LACTIC ACID BACTERIA TO REDUCE ATHEROSCLEROSIS
WO2016127019A3 (en) Pharmaceutical compositions for combination therapy
GB2459809A (en) Fatty acid formulations and methods of use thereof
WO2006086108A3 (en) Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors
BR112013020167A2 (en) permeation enhancers for topical formulations
SG193246A1 (en) Nutritional compositions for increasing arginine levels and methods of using same
MX2009012782A (en) Formulations for the oral administration of therapeutic agents and related methods.
WO2009048249A3 (en) Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same
ATE413865T1 (en) COMPOSITIONS WITH ALPHAHYDROXY ACID ESTERS FOR THE RELEASE OF ACTIVE INGREDIENTS AND METHODS OF USE THEREOF
NO20005718A (en) Composition for skin containing chitosan-conjugated CLA and chitosan-conjugated vitamin A or a &lt;beta&gt; -cyclodextrin-conjugated vitamin A and methods for its preparation and use
MX2009009838A (en) Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents.
TW201350107A (en) Topical pharmaceutical compositions
MX351222B (en) Clear or translucent composition.
MX2012007227A (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture.
MX2021002902A (en) Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient.
MX2007006775A (en) Stable compositions of fenofibrate with fatty acid esters.
EA201291335A1 (en) PHARMACEUTICAL COMPOSITIONS FOR LOCAL APPLICATION
WO2023174948A3 (en) Compositions having improved bioavailability of therapeutics and uses thereof
TR201903470T4 (en) Formulation for personal hygiene.
PE20061101A1 (en) FOOD SUPPLEMENT WITH SPECIFICALLY EQUIVALENT MAGNESIUM AND POTASSIUM CITRATE
CA2865557A1 (en) Gelling formulation based on calcium gluconate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 315617

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2023233811

Country of ref document: AU

Date of ref document: 20230314

Kind code of ref document: A